Presented by: Ganesh Anand, Associate Professor, Ph.D., National University of Singapore and Kai Zhang, Consultant Biologist, Lilly Biotechnology Center
This webinar was hosted live on December 2, 2015 by GEN
Scientists are always on the hunt for new analytical approaches that will streamline the biotherapeutic characterization process and answer questions found intractable using traditional methodologies. One such technique, hydrogen deuterium exchange mass spectrometry (HDX-MS)—a biophysical tool for characterizing protein conformation and dynamics—has become an indispensable method to answer important questions concerning therapeutic protein structure, stability, and interactions. Additionally, the correlation of HDX-MS profiles for a target protein interacting with a panel of ligands has facilitated the determination of structure-function relationships, and differentiated new ligand classes based on selective binding.
Our panelists for this webinar will discuss their experiences using HDX-MS for simplifying the process of selecting the most promising new biopharmaceutical entities for therapeutic intervention, and for understanding the interactions between a therapeutic and its biological target.
The first presentation will be given by Associate Professor Ganesh Anand, Ph.D., a leading expert on HDX-MS at the National University of Singapore. Dr. Anand will discuss his recent work using HDX-MS to identify lead fragment compounds through protein-ligand binding studies, and exciting new research to uncover novel sites within macromolecular assemblies including viruses with high potential to serve as targets for new interventional therapies.
Our second presenter, Kai Zhang is a consultant biologist at the Lilly Biotechnology Center located in San Diego. Ms. Zhang will discuss her work on epitope and paratope mapping studies of monoclonal antibodies using HDX-MS, and its ability to advance proteins through biopharmaceutical drug discovery.